Lepu
Location: China
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 5
| Date | Title | Description |
| 04.03.2025 | China's Lepu Biopharma Falls After New Cancer Drug's Approval Is Delayed | (Yicai) March 4 -- Shares of Lepu Biopharma dropped after the Chinese biopharmaceutical firm said it had to resubmit its application to sell a new nasopharyngeal carcinoma treatment in China amid the country's drug regulator having not yet ... |
| 23.01.2025 | The Rise of Innovative Cancer Therapies: A New Era in Oncology | The landscape of cancer treatment is evolving. New players are entering the field, armed with innovative therapies that promise to change the game. Two recent developments from Lepu Biopharma and Akeso Inc. highlight this shift. Both compan... |
| 22.01.2025 | Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers | HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody-... |
| 22.01.2025 | Akeso Received Payment for the Development Collaboration on Tagitanlimab | HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on ... |
| 21.11.2024 | DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation | This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a... |